TY - JOUR T1 - Should international borders re-open? The impact of travel restrictions on COVID-19 importation risk JF - medRxiv DO - 10.1101/2020.10.11.20211060 SP - 2020.10.11.20211060 AU - Jessica Liebig AU - Kamran Najeebullah AU - Raja Jurdak AU - Ahmad El Shoghri AU - Dean Paini Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/14/2020.10.11.20211060.abstract N2 - Novel coronavirus disease (COVID-19) has spread across the world at an unprecedented pace, reaching over 200 countries and territories in less than three months. In response, many governments denied entry to travellers arriving from various countries affected by the virus. While several industries continue to experience economic losses due to the imposed interventions, it is unclear whether the different travel restrictions were successful in reducing COVID-19 importations. Here we develop a comprehensive framework to model daily COVID-19 importations, considering different travel bans. We quantify the temporal effects of the restrictions and elucidate the relationship between incidence rates in other countries, travel flows and the expected number of importations into the country under investigation. As a cases study, we evaluate the travel bans enforced by the Australian government. We find that international travel bans in Australia lowered COVID-19 importations by 87.68% (83.39 - 91.35) between January and June 2020. The presented framework can further be used to gain insights into how many importations to expect should borders re-open. Authorities may consider the presented information when planning a phased re-opening of international borders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The authors obtained approval from CSIRO's ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Australian arrival card data is available at https://data.gov.au/dataset/ds-dga-5a0ab398-c897-4ae3-986d-f94452a165d7/details?q=arrival\%20card\%20data. COVID-19 data is available at https://www.ecdc.europa.eu/en/publications-data/download-todays-data-geographic-distribution-covid-19-cases-worldwide. Passenger flows from Australia to New Zealand are available at https://www.bitre.gov.au/publications/ongoing/international\_airline\_activity-monthly\_publications. New Zealand COVID-19 importation data is available at https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-current-situation/covid-19-current-cases/covid-19-current-cases-details\#download. COVID-19 importation data for NSW was obtained from NSW Health and is not publicly available. ER -